Atopic Dermatitis Drugs Market – By Product, By Route of Administration, By Application, By End Use - Global Forecast 2025 – 2034

Atopic Dermatitis Drugs Market Size

The global atopic dermatitis drugs market size was valued at around USD 12.1 billion in 2024 and is estimated to grow at 9.9% CAGR from 2025 to 2034. Atopic dermatitis drugs are pharmaceutical treatments to treat atopic dermatitis (AD) and its associated skin symptoms, including inflammation, itching, and skin dryness. These drugs focus on curing flare-ups, inflammation and controlling skin condition. These drugs include topical treatments, systemic treatments, and biological medicines that vary according to the severity of the condition.
 

There is an expected growth in the atopic dermatitis market due to the rise in the occurrence of atopic dermatitis, strong drug pipeline, new biologics, and untapped opportunities for growth. The cases of atopic dermatitis are continually growing. According to the International Eczema Council, in 2022, atopic dermatitis impacted nearly 20% of children and around 10% of adults worldwide. The condition has considerable economic and societal impacts, and it has been marked as the most debilitating skin disease. This implies a continued supply of therapeutic medications in the foreseeable future.
 

Also, the atopic dermatitis market is seeing considerable spending on research and development as the pharmaceutical firms attempt to launch new products. The large industry players are likely to benefit in the next few years from rising revenues due to an increase in favourable outcomes from late-stage clinicals trial drugs. For instance, in April 2021, Galderma Laboratories reported beneficial phase 2b results for their uncontrolled atopic dermatitis drug nemolizumab.
 

Similarly, in March 2021, Pfizer confirmed that their developmental drug, abrocitinib, was found not to be inferior to Sanofi’s well-established treatment, Dupixent. Additionally, there is an unmet need for oral medications in this disease which can be met by abrocitinib, a JAK1 inhibitor, in the atopic dermatitis patient population that requires treatment with oral medications. These advancing drug pipelines, alongside expected new oral medications, are expected to boost the expansion of the atopic dermatitis market.
 

Atopic Dermatitis Drugs Market Trends

• Growth in the atopic dermatitis market is expected owing to increasing approval of products and the introduction of new biologics for the management of the disease, especially in children. For instance, in June 2022, Sanofi received FDA approval for Dupixent (dupilumab) for use in atopic dermatitis in children six months to 5 years old.
   
• Also, in January 2022, AbbVie received FDA approval for RINVOQ (upadacitinib) for atopic dermatitis in patients 12 years and older. RINVOQ was approved for patients who had not previously responded to other injectable or oral treatments. These changes to product approvals and increased treatment options are expected to improve market growth.
   
• In addition, the atopic dermatitis treatment paradigm is changing with the inclusion of biologic therapies such as monoclonal antibodies, Dupixent and Rinvoq, which are more specific for the underlying pathogenic mechanisms of the disease. Biologic therapy is more effective and provides long-term relief to patients, particularly those with moderate to severe atopic dermatitis.
   

Atopic Dermatitis Drugs Market Analysis

Based on drug class, the market is segmented into corticosteroids, calcineurin inhibitors, biologics, phosphodiesterase-4 (PDE-4) inhibitors, and other drug classes. The global market for atopic dermatitis drugs was valued at USD 11.1 billion in 2023. The biologics segment dominated the market with the largest revenue share of 41.3% in 2024.
 

• Biologics offer treatment options that can be both more effective and targeted. The greater adoption of these products is due to the fact that they can control symptoms over the long term, decrease flare-ups, and improve patients’ overall life quality.
   
• Moreover, the segment of biologics is growing further because of high demand owing to greater efficacy, an increase in product approvals, and a strong atopic dermatitis biologic drug pipeline. For instance, Galderma Laboratories is currently researching the efficacy of nemolizumab, a monoclonal antibody, for the treatment of pruritus and atopic dermatitis.

Based on route of administration, the atopic dermatitis drugs market is segmented into injectable, topical, and oral. The injectable segment dominated the market with the largest revenue share of 45.1% in 2024.
 

• The expansion of injectable options for atopic dermatitis is due to the development of new biologic drugs that target distinct inflammatory pathways including IL-4, IL-13, and JAK inhibitors. This diversification of therapeutic options is a major factor of growth in the injectable segment.
   
• Similarly, the U.S FDA and EMA have authorized the use of several injectable biologics for the treatment of atopic dermatitis, which has expediated their market entry and availability. The rapid approval of these drugs in large markets is increasing their adoption rates.
   
• For instance, in September 2024, Eli Lilly and Company reported that their EBGLYSS (lebrikizumab-lbkz) 250 mg/2ml injection was approved by the U.S. FDA, which is a targeted IL-13 inhibitor for the treatment of patients aged twelve years and older.
   

Based on patient demographics, the atopic dermatitis drugs market is bifurcated into pediatric and adults. The pediatric segment dominated the market with the largest revenue of USD 8.7 billion in 2024.
 

• The increasing incidence of atopic dermatitis, particularly amongst children, remains an important driver for the pediatric treatment market. For instance, the National Eczema Association suggests that roughly 1 in 10 people will get AD with the greatest incidence during their early childhood years. Such a high incidence is generating a stronger need for appropriate treatment options designed for children which is in turn, growing the market for pediatric atopic dermatitis therapeutics.
   
• Additionally, the new market opportunities are also fueled by the approval of new treatment therapies for pediatric use. For instance, in May 2020, the federal Drug Administration (FDA) gave marketing authorization to Dupixent for the treatment of children aged 6 to 11 years with moderate-to-severe atopic dermatitis, which is a remarkable advancement in pediatric dermatology.
   
• In addition, the expansion of the market is being aided by the FDA's accelerated approval of pediatric formulations of biologic therapy drugs. This would lead to increased market growth along with innovative products and services being available more rapidly, which would benefit children suffering from atopic dermatitis.
   

Based on distribution channel, the atopic dermatitis drugs market is segmented into hospital pharmacies, retail pharmacies, and e-commerce. The hospital pharmacies segment dominated the market with the largest revenue of USD 5.8 billion in 2024.
 

• Hospital pharmacies are essential in the treatment of atopic dermatitis for these patients who need to be hospitalized, particularly when the patient requires extensive treatment, and their medications are not available at retail pharmacies.
   
• These pharmacies also serve an equally important role in monitoring patients receiving systemic biologic therapies or other such medications in terms of their side effects and treatment outcomes. The clinical setting is ideal for the supervision of medical treatment that needs careful administration or has side effects, such as biologics.

The U.S. atopic dermatitis drugs market revenue has increased considerably from USD 4.7 billion in 2023 and is expected to grow significantly, reaching USD 13.1 billion by 2034.
 

• U.S. based organizations, for instance, the National Eczema Association (NEA), are helping increase the level of understanding of atopic dermatitis and its consequences. These organizations advocate for more appropriate research, funding, as well as better access to medications. The NEA, for instance, announced in March 2022 the opening of its 2022 research grant cycle for awards of eczema related research totaling USD 760,000. The efforts of these organizations mobilize public and healthcare industry attention towards new and effective treatments and therapies which can improve outcomes and quality of life for millions of people around the globe.
   
• In addition, the grant was awarded by the U.S. Food and Drug Administration (FDA) for speed approval on the number of biologic medications for atopic dermatitis, especially strongly expressed in children and severe patients.
   
• For instance, the FDA in February 2021 gave Fast-Track designation to Asana BioSciences' oral dual inhibitor of Janus Kinase (JAK) and Spleen Tyrosine Kinase (SYK), - gusacitinib (ASN002), intended for treatment of moderate-to-severe Chronic Hand Eczema (CHE). The support from regulatory authorities has led to a quicker market introduction of new medicines that are greatly needed in the rapidly evolving atopic dermatitis market.
   

Europe: The atopic dermatitis drugs market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The increase in allergies and environmental factors such as pollution in the UK is resulting in a higher incidence of atopic dermatitis. For instance, the Department for Environment, Food & Rural Affairs (DEFRA) highlighted that air pollution in many cities is above the recommendations of the World Health Organization (WHO). This points towards the need for further therapies that not only improve the symptoms of atopic dermatitis but also tackle its root cause.
   
• In addition, the healthcare systems in the UK allows reimbursement for effective and expensive biologics and JAK inhibitors making it easier for patients to access the therapy. For instance, Leo Pharma’s Adtralza, which is a biologic drug, and the IL-13 blocker was reimbursed by National Institute for Health and Care Excellence (NICE) in June 2022.
   

Asia Pacific: Japan atopic dermatitis drugs market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Atopic dermatitis (AD) affects an increasing percentage of Japan's population, with a higher prevalence among children and young adults. For instance, the National Institute of Health (NIH) reported that the rate of AD among children in mainland Japan is 12-13 percent.
   
• The high prevalence of AD cases is due to urbanization, changes in the environment, and westernized diet which has caused an increase in inflammatory and allergic skin diseases which caused a higher need for efficient treatments.
   

Middle East and Africa: The atopic dermatitis drugs market in Saudi Arabia is expected to experience significant and promising growth from 2025 to 2034.
 

• Saudi Arabia's weather greatly affects skin maladies like atopic dermatitis, and makes them worse, as it causes skin dryness and increases the risk of flaring up. Increased pollution and exposure to sandstorms worsen sensitivity and raises the demand for better effective atopic dermatitis treatments.
   
• For instance, the Saudi Ministry of Health indicated that the pollution levels in the Saudi Arabian air tends to go over the WHO guidelines in the major cities. The average particulate matter (PM2.5) level was around 81 µg/m³ during the year 2023 which is extremely higher than the annually required value of 5 µg/m³. These factors are very much at the frontline when it comes to atopic dermatitis and require proper plans for management and treatment.
   

Atopic Dermatitis Drugs Market Share

The market is competitive, featuring both major global companies and numerous smaller firms. The top 5 players in this market include Sanofi, Regeneron Pharmaceuticals, AbbVie, Pfizer, and LEO Pharma. These players collectively account for approximately 45% market share. These players are investing in the development of advanced treatments to enhance treatment efficiency. Moreover, strategic partnerships with research institutions and healthcare providers are critical for integrating modern technologies and expanding distribution, which will enable the companies to address the surge in demand for non-invasive and cost-effective solutions. The market experiences a regulatory support and streamlined approval processes which further motivates to innovate and facilitates market entry. Additionally, emerging players such as Dermavant Sciences and Incyte Corporation are focussing on development of new treatments, including topical and JAK inhibitor therapies, which aim to improve disease management. These innovations continue to promote market progression.
 

Atopic Dermatitis Drugs Market Companies

Some of the eminent market participants operating in the atopic dermatitis drugs industry include:

• AbbVie
• Arcutis Biotherapeutics
• Eli Lilly and Company
• Galderma Laboratories
• Incyte Corporation
• Leo Pharma
• Maruho
• Novartis
• Otsuka Pharmaceutical
• Pfizer
• Regeneron Pharmaceuticals
• Sanofi
• Viatris
   
• Sanofi is one of the leading player in the market of atopic dermatitis drugs. Dupixent (dupilumab), the first FDA-approved biologic therapy for AD, demonstrating high efficacy and safety. The drug has achieved multi-billion-dollar sales, building a strong market share for the company.
   
• AbbVie is a global company with a strong presence worldwide which makes its distribution network stronger. The company has its presence in more than 175 countries. The company’s portfolio includes Rinvoq (upadacitinib), a JAK inhibitor which provides an oral alternative to biologics.
   
• Pfizer has a strong R&D pipeline and dominance in small-molecule drugs, with expertise in JAK inhibitors such as Cibinqo (abrocitinib). It also has presence in more than 165 countries, making it a global player.
   

Atopic Dermatitis Drugs Industry News:

• In May 2024, Johnson & Johnson announced the acquisition of Proteologix, a private biotechnology firm specializing in bispecific antibodies for immune-mediated diseases. Through this acquisition, J&J acquired Proteologix’s portfolio, including PX128, a bispecific antibody targeting IL-13 and TSLP, set to enter phase 1 trials for moderate-to-severe atopic dermatitis and asthma, and PX130, targeting IL-13 and IL-22, in preclinical development for moderate-to-severe atopic dermatitis. The acquisition also provided J&J with additional bispecific antibody programs, enhancing its capacity to develop innovative treatments across various diseases.
   
• In January 2024, Pfizer and Glenmark Pharma collaborated to launch abrocitinib, an advanced oral systemic treatment for moderate-to-severe atopic dermatitis, in India. Developed by Pfizer, abrocitinib received marketing authorization from India’s Central Drugs Standard Control Organization and approval from the US FDA, EMA, and other regulatory bodies, according to a company statement. This launch strengthened both companies' presence in the dermatology market.
   

The atopic dermatitis drugs market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Corticosteroids
• Calcineurin inhibitors
• Biologics
• Phosphodiesterase-4 (PDE-4) inhibitors
• Other drug classes

Market, By Route of Administration

• Topical
• Oral
• Injectable

Market, By Patient Demographics

• Pediatric
• Adults

Market, By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE